Provider: Ingenta Connect
Database: Ingenta Connect
Content: application/x-research-info-systems
TY - ABST
AU - Cerchia, L.
AU - de Franciscis, V.
TI - Nucleic Acid Aptamers Against Protein Kinases
JO - Current Medicinal Chemistry
PY - 2011-09-01T00:00:00///
VL - 18
IS - 27
SP - 4152
EP - 4158
KW - Aptamers
KW - cancer
KW - SELEX
KW - intracellular kinases
KW - RNA-bioconjugates
KW - transmembrane kinases
KW - transmembrane
N2 - Deregulation of kinase function has been implicated in several important diseases, including cancer, neurological and metabolic disorders. Because of their key role in causing disease, kinases have become one of the most intensively pursued classes of drug targets. To date, several
monoclonal antibodies (mAbs) and small-molecule inhibitors have been approved for the treatment of cancer. Aptamers are short structured single stranded RNA or DNA ligands that bind at high affinity to their target molecules and are now emerging as promising molecules to target specific cancer
epitopes in clinical diagnosis and therapy. Further, because of their high specificity and low toxicity aptamers will likely reveal among the most promising molecules for in vivo targeted recognition as therapeutics or delivery agents for nanoparticles, small interfering RNAs bioconjugates,
chemotherapeutic cargos and molecular imaging probes.
In this article, we discuss recent advances in the development of aptamers targeting kinase proteins.
UR - https://www.ingentaconnect.com/content/ben/cmc/2011/00000018/00000027/art00006
M3 - doi:10.2174/092986711797189592
UR - https://doi.org/10.2174/092986711797189592
ER -